Cite
HARVARD Citation
Cordero, A. et al. (n.d.). LDLc reduction with fixed-dose combination rosuvastatin-ezetimibe in patients with coronary heart disease that are not candidates for PCSK9 inhibitors treatment. European heart journal. p. . [Online].